|
| 37778952 | Pembrolizumab with or Without Lenvatinib as First-line Therapy for Patients with Advanced Urothelial Carcinoma (LEAP-011): A Phase 3, Randomized, Double-Blind Trial. | Eur Urol | 2024 |
| 35039605 | Real-world evidence of patients with metastatic castration-resistant prostate cancer treated with cabazitaxel: comparison with the randomized clinical study CARD. | Prostate Cancer Prostatic Dis | 2023 |
| 37509315 | Immunotherapy in Urothelial Cancer: Stop When Achieving a Response, Restart upon Disease Progression. | Cancers (Basel) | 2023 |
| 37536738 | <sup>68</sup>Ga-PSMA PET/CT for Response Evaluation of <sup>223</sup>Ra Treatment in Metastatic Prostate Cancer. | J Nucl Med | 2023 |
| 37087376 | PARP Inhibitors for Prostate Cancer: Tangled up in PROfound and PROpel (and TALAPRO-2) Blues. | Eur Urol | 2023 |
| 36983083 | A Compendium of AR Splice Variants in Metastatic Castration-Resistant Prostate Cancer. | Int J Mol Sci | 2023 |
| 37312054 | The CHASIT study: sequential chemo-immunotherapy in patients with locally advanced urothelial cancer - a non-randomized phase II clinical trial. | BMC Cancer | 2023 |
| 37178439 | mFast-SeqS-based aneuploidy score in circulating cell-free DNA is a prognostic biomarker in prostate cancer. | Mol Oncol | 2023 |
| 37073813 | Effect of docetaxel added to bicalutamide in Hormone-Naïve non-metastatic prostate cancer with rising PSA, a randomized clinical trial (SPCG-14). | Acta Oncol | 2023 |
| 37071834 | Cardiovascular Disease in Testicular Cancer Survivors: Identification of Risk Factors and Impact on Quality of Life. | J Clin Oncol | 2023 |
| 37269569 | Validation of an LC-MS/MS method for simultaneous quantification of abiraterone, enzalutamide and darolutamide in human plasma. | J Chromatogr B Analyt Technol Biomed Life Sci | 2023 |
| 37031196 | Predicting response to enzalutamide and abiraterone in metastatic prostate cancer using whole-omics machine learning. | Nat Commun | 2023 |
| 36494006 | Efficacy and safety of pembrolizumab in metastatic urothelial carcinoma: results from KEYNOTE-045 and KEYNOTE-052 after up to 5 years of follow-up. | Ann Oncol | 2023 |
| 35976415 | A blood-based immune marker for resistance to pembrolizumab in patients with metastatic urothelial cancer. | Cancer Immunol Immunother | 2023 |
| 34615720 | Anti-PD-1 Efficacy in Patients with Metastatic Urothelial Cancer Associates with Intratumoral Juxtaposition of T Helper-Type 1 and CD8<sup>+</sup> T cells. | Clin Cancer Res | 2022 |
| 35677318 | Neutropenia, neutrophilia, and neutrophil-lymphocyte ratio as prognostic markers in patients with metastatic castration-resistant prostate cancer. | Ther Adv Med Oncol | 2022 |
| 35568678 | Adding metabolic agents to prostate cancer therapy: Every rose has its thorn. | Eur J Cancer | 2022 |
| 35388003 | Predictive biomarkers for survival benefit with ramucirumab in urothelial cancer in the RANGE trial. | Nat Commun | 2022 |
| 35895277 | Influence of Darolutamide on Cabazitaxel Systemic Exposure. | Clin Pharmacokinet | 2022 |
| 36323051 | CABA-V7: a prospective biomarker selected trial of cabazitaxel treatment in AR-V7 positive prostate cancer patients. | Eur J Cancer | 2022 |
| 35314962 | Being Transparent About Brilliant Failures: An Attempt to Use Real-World Data in a Disease Model for Patients with Castration-Resistant Prostate Cancer. | Drugs Real World Outcomes | 2022 |
| 35248823 | Circulating tumour cells to drive the use of neoadjuvant chemotherapy in patients with muscle-invasive bladder cancer. | ESMO Open | 2022 |
| 35247908 | Putative Biomarkers of Clinical Benefit With Pembrolizumab in Advanced Urothelial Cancer: Results from the KEYNOTE-045 and KEYNOTE-052 Landmark Trials. | Clin Cancer Res | 2022 |
| 35181986 | Genome-wide aneuploidy detected by mFast-SeqS in circulating cell-free DNA is associated with poor response to pembrolizumab in patients with advanced urothelial cancer. | Mol Oncol | 2022 |
| 35086719 | Comprehensive Molecular Characterization Reveals Genomic and Transcriptomic Subtypes of Metastatic Urothelial Carcinoma. | Eur Urol | 2022 |
| 35029306 | Exposure-response relationship of ramucirumab in RANGE, a randomized phase III trial in advanced urothelial carcinoma refractory to platinum therapy. | Br J Clin Pharmacol | 2022 |
| 31601523 | Real-world Outcomes of Sequential Androgen-receptor Targeting Therapies with or Without Interposed Life-prolonging Drugs in Metastatic Castration-resistant Prostate Cancer: Results from the Dutch Castration-resistant Prostate Cancer Registry. | Eur Urol Oncol | 2021 |
| 33738495 | Cabazitaxel versus abiraterone or enzalutamide in metastatic castration-resistant prostate cancer: post hoc analysis of the CARD study excluding chemohormonal therapy for castrate-naive disease. | Jpn J Clin Oncol | 2021 |
| 33822655 | Predicting Outcomes in Men With Metastatic Nonseminomatous Germ Cell Tumors (NSGCT): Results From the IGCCCG Update Consortium. | J Clin Oncol | 2021 |
| 33820747 | Financial Toxicity Among Patients with Prostate, Bladder, and Kidney Cancer: A Systematic Review and Call to Action. | Eur Urol Oncol | 2021 |
| 33729863 | Survival and New Prognosticators in Metastatic Seminoma: Results From the IGCCCG-Update Consortium. | J Clin Oncol | 2021 |
| 33930524 | Outcomes of treatment choices in poor prognosis prostate cancer: not against all odds. | Ann Oncol | 2021 |
| 33805793 | Pain Progression at Initiation of Cabazitaxel in Metastatic Castration-Resistant Prostate Cancer (mCRPC): A Post Hoc Analysis of the PROSELICA Study. | Cancers (Basel) | 2021 |
| 33799049 | Cross-resistance and drug sequence in prostate cancer. | Drug Resist Updat | 2021 |
| 33579196 | Diagnostic yield of colonoscopy surveillance in testicular cancer survivors treated with platinum-based chemotherapy: study protocol of a prospective cross-sectional cohort study. | BMC Gastroenterol | 2021 |
| 33497248 | Initial Management of Noncastrate Advanced, Recurrent, or Metastatic Prostate Cancer: ASCO Guideline Update. | J Clin Oncol | 2021 |
| 33746212 | The effects of new life-prolonging drugs for metastatic castration-resistant prostate cancer (mCRPC) patients in a real-world population. | Prostate Cancer Prostatic Dis | 2021 |
| 34749299 | Continued androgen signalling inhibition improves cabazitaxel efficacy in prostate cancer. | EBioMedicine | 2021 |
| 34478664 | Pembrolizumab monotherapy for high-risk, non-muscle invasive bladder cancer - Authors' reply. | Lancet Oncol | 2021 |
| 34450475 | Baseline neutrophil-to-lymphocyte ratio as a predictive and prognostic biomarker in patients with metastatic castration-resistant prostate cancer treated with cabazitaxel versus abiraterone or enzalutamide in the CARDÂ study. | ESMO Open | 2021 |
| 34274136 | Efficacy and Safety of Cabazitaxel Versus Abiraterone or Enzalutamide in Older Patients with Metastatic Castration-resistant Prostate Cancer in the CARD Study. | Eur Urol | 2021 |
| 33932725 | Generating human prostate cancer organoids from leukapheresis enriched circulating tumour cells. | Eur J Cancer | 2021 |
| 33974560 | 11-Ketotestosterone is the predominant active androgen in prostate cancer patients after castration. | JCI Insight | 2021 |
| 32059957 | Liquid Biopsies to Select Patients for Perioperative Chemotherapy in Muscle-invasive Bladder Cancer: A Systematic Review. | Eur Urol Oncol | 2021 |
| 33218827 | Use of Chemotherapy and Androgen Signaling-targeted Inhibitors in Patients with Metastatic Prostate Cancer. | Eur Urol | 2021 |
| 33119475 | Dose-Dependent Effect of Platinum-Based Chemotherapy on the Risk of Metachronous Contralateral Testicular Cancer. | J Clin Oncol | 2021 |
| 31412001 | Cost-effectiveness of Pembrolizumab as Second-line Therapy for the Treatment of Locally Advanced or Metastatic Urothelial Carcinoma in Sweden. | Eur Urol Oncol | 2020 |
| 31753727 | Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): overall survival and updated results of a randomised, double-blind, phase 3 trial. | Lancet Oncol | 2020 |
| 31837907 | Impact of progression at baseline and on-treatment progression events in three large prostate cancer trials. | Eur J Cancer | 2020 |
| 31893292 | The influence of single-nucleotide polymorphisms on overall survival and toxicity in cabazitaxel-treated patients with metastatic castration-resistant prostate cancer. | Cancer Chemother Pharmacol | 2020 |